Eli Lilly & Novartis are entering a strategic research collaboration with Isomorphic Labs to use state-of-the-art AI technologies—including the next-gen model of #AlphaFold—to discover novel small molecule therapeutics for select biological targets.

We are reimagining the entire drug discovery process from first principles with an AI-first approach.